This trial is testing a new drug, CX-4945, for patients with a specific type of brain cancer that has come back after treatment.
4 Primary · 5 Secondary · Reporting Duration: Up to 3 years from enrollment
Awards & Highlights
3 Treatment Groups
Phase I - Skeletally-immature
1 of 3
Phase II - Skeletally-mature
1 of 3
1 of 3
60 Total Participants · 3 Treatment Groups
Primary Treatment: CX 4945 · No Placebo Group · Phase 1 & 2
Who is running the clinical trial?
Age Any Age · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
How many individuals are being helped by this research?
"That is correct, the available information does point to this clinical trial being open for recruitment. The original posting was on March 18th, 2019 with the most recent update coming on August 30th, 2022. They are trying to enroll 60 individuals at 12 different locations." - Anonymous Online Contributor
Are people still signing up for this experiment?
"The most up-to-date information indicates that this trial is actively recruiting patients. The listing was first posted on March 18th, 2019 and was last updated on August 30th, 2020." - Anonymous Online Contributor
Are research facilities in Canada actively pursuing this line of inquiry?
"A total of 12 sites are recruiting patients for this clinical trial, with Memorial Sloan-Kettering Cancer Center in New York, Baylor College of Medicine in Houston, and Ann & Robert H. Lurie Children's Hospital of Chicago in Chicago amongst them." - Anonymous Online Contributor
Do we have any previous data to review for CX 4945?
"So far, CX 4945 has been trialled 3 times with the most recent study taking place at Grenoble Alps Hospital in 2017. Presently, there are 3 more ongoing clinical trials, one of which is based in New York City." - Anonymous Online Contributor
What are the ultimate goals of this experiment?
"The purpose of this 4-week trial is to study the efficacy of CX-4945 in skeletally-mature subjects with advanced solid tumors. The primary endpoint is response rate, as measured by PR or CR, and secondary objectives include reduction in CK2 activity, percentage of genomic alterations, and plasma drug concentration of CX-4945." - Anonymous Online Contributor